Breaking News

Almac Discovery Licenses Cancer Drug

Shin Poong to develop and market ALM201 in South Korea

Author Image

By: Tim Wright

Editor-in-Chief, Contract Pharma

Almac Discovery has licensed its novel anti-angiogenic peptide ALM201 to Shin Poong Pharmaceutical Co. Ltd. for clinical development and marketing in South Korea. Almac will receive an undisclosed upfront payment, milestones and royalties. Almac Discovery will pursue its own development program in Europe and is seeking partners for ALM201 in all other territories.   ALM201 is a highly potent anti-angiogenic peptide targeted to cells expressing CD44 and acts by inhibiting migration of vascular en...

Continue reading this story and get 24/7 access to Contract Pharma for FREE


Already a subscriber? Sign in

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters